A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282, Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)

Administered By

Awarded By

Contributors

Start/End

  • November 1, 2015 - April 30, 2019